Eli Lilly and Company is trading 3.4% up at $1,170.00 after releasing highly positive late-stage clinical data for its next-generation obesity drugs presented at the American Diabetes Association meeting.
- Investors are reacting to encouraging Phase 3 and late-stage results for obesity candidates Foundayo and retatrutide.
- The new data reinforces the company's leadership position and growth potential within the global obesity and diabetes treatment markets.